The numbers tell a story most boards have not caught up with.

A market in structural transition

UK dentistry has undergone a more significant commercial transformation in the last decade than in the preceding fifty years. The total UK dental market was valued at £12.16 billion in 2023/24, a 9.2 per cent increase year on year. Private dentistry now accounts for 69 per cent of that total, the highest share recorded since LaingBuisson began tracking the sector in 2007, up from a private revenue share of closer to 51 per cent five years ago. The market is growing, and its character is changing.

UK dental market revenue split  |  2023/24

Three forces are driving this. NHS dental provision is structurally constrained by a contract model that, in the words of the British Dental Association, leaves typical NHS contract holders delivering care at a loss and reliant on a cross-subsidy of over £400 million a year from private activity to break even. Patient access has deteriorated to the point where 36 per cent of people turning to private dental care in 2024 did so because they could not access NHS treatment at all. And a decade of private equity-backed consolidation has created a corporate dental tier, approximately 2,200 practices across groups of 30 or more sites, that thinks and operates at an entirely different level of commercial sophistication from the independent practice of a generation ago.

Layered on top of these structural pressures are rising operational costs. Increases to employers' National Insurance contributions and the National Minimum Wage have added cost pressure across all operators, felt most acutely in NHS practices where contract values are fixed. These headwinds are accelerating the shift toward mixed and private income models as operators seek the margin headroom that NHS-only delivery alone no longer provides.

The market is more dynamic than a simple privatisation narrative captures. NHS goodwill multiples have recently reversed direction: contract changes including updates to fluoride application and unscheduled care remuneration are creating new profitability opportunities within the NHS model, and NHS goodwill values are now outperforming many mixed and private practice transactions. The revenue balance has shifted substantially toward private over five years, and that shift is structural. But the market is not simply moving in one direction. It is becoming more commercially sophisticated in how it reads and responds to both segments simultaneously.

Private dentistry share of total market revenue  |  five-year shift

The consolidation opportunity has not closed. It has matured.

What consolidation has actually produced

UK dental market structure  |  12,223 practices

The consolidation narrative in UK dental has been running for over fifteen years. The headline story, PE firms buying up independent practices to create scale, is well understood. What is less well understood is what that consolidation has actually produced at the level of the business, and where it has left the sector as it enters a more mature and more scrutinised phase.

The first wave of consolidation, roughly 2010 to 2020, was primarily about aggregation. Roll up enough practices, standardise basic operations, extract central procurement savings, and hold until exit. Multiples were rising, capital was cheap, and governance was, in many cases, an afterthought. The quality of integration work varied enormously. Cultural mismatches between clinically-led practice cultures and commercially-driven group management were widespread and are still being worked through.

The second wave, which the market is now entering, is different in character. Corporate buyers re-entering the market in the first half of 2025, per Christie & Co, are doing so with a renewed focus on quality over scale. Many larger groups spent 2023 and 2024 refining their portfolios and operating models rather than acquiring. The deals that are getting done are more targeted and structurally more sophisticated, with 36 per cent of corporate and large group transactions in 2024 and the first half of 2025 involving deferred consideration, compared to 12 per cent for small groups and independents.

The landmark transaction of the cycle was Bridgepoint's acquisition of a majority stake in mydentist, completed in July 2025 and valued at approximately £800 million. It is the largest deal the UK dental sector has seen and a clear signal of institutional confidence in the sector's long-term trajectory. Alongside the scale transactions, new entrants are changing how consolidation works. DeNovo Dental Partners launched in early 2025 with the acquisition of six practices across the South of England, introducing a shared ownership model that is a structurally different approach from the traditional PE roll-up. The playbook is broadening.

The mid-market, groups of three to 29 sites, is where the most significant opportunity is developing. These businesses are large enough to have real operational complexity but small enough that governance infrastructure is often underdeveloped relative to the commercial ambition of their owners. PE firms including Bridgepoint, Core Equity, Synova, and August Equity have all been active in UK healthcare. The dental mid-market represents an attractive entry point for the next consolidation cycle, but only for businesses that can withstand the scrutiny that now accompanies a PE transaction.

The regulator has arrived. The question is whether boards were ready.

The regulatory inflection point

The Competition and Markets Authority launched a formal market study into private dentistry in March 2026, at the request of the Chancellor. The study is examining pricing transparency, consumer choice, competition dynamics, business conduct, and complaints and redress. Its final report is due in March 2027. The CMA's scope is explicit that corporate structures, ownership models, and the potential for vertical integration to affect patient choice are areas of active scrutiny.

This matters for governance in a specific way. A CMA market study does not automatically lead to enforcement, but its recommendations carry weight with government and will almost certainly shape regulatory expectations for the sector over the following three to five years. The direction of travel is clear: greater transparency, more rigorous consumer protection, and closer examination of how corporate dental groups compete at a local level.

CMA focus area	What the CMA is examining	Governance implication
Pricing transparency	Whether fees are clearly disclosed upfront and consistently applied across sites	Group boards need documented pricing governance and audit trails. Inconsistent fee structures across a portfolio create compliance and reputational exposure.
Corporate structures	Whether ownership models or vertical integration affect patient choice	PE-backed groups and multi-entity structures face the most scrutiny. Boards need to demonstrate how group structure serves patient interests.
Marketing and patient information	Claims made online, financing promotions, accuracy of treatment descriptions	Marketing governance and sign-off processes need to be board-level rather than delegated entirely to marketing functions.
Competition dynamics	Local market concentration where a small number of providers dominate	Acquisition strategy needs governance oversight. Boards should be asking concentration questions before completing acquisitions, not after.
Complaints and redress	Whether patients can effectively resolve disputes	Complaint escalation pathways and resolution data need to be visible at board level, not just managed at practice level.

The CMA study is not an isolated event. It sits within the CMA's 2026 to 2029 strategy, which explicitly prioritises action in essential areas of household spend including healthcare. Boards that treat this as a compliance exercise rather than a governance signal will be caught out by the regulatory requirements that follow the final report.

Technology decisions made below board level become board-level problems.

The technology layer

AI is entering dental operations faster than most boards have registered. The conversation in the sector has been dominated by clinical AI: diagnostic imaging, treatment planning tools, and chairside decision support. These are real and developing, but they are not where the immediate operational leverage lies for a group operator or a PE-backed DSO. Christie & Co's Business Outlook 2026 is unambiguous on the direction of travel, predicting that AI, CRM, and digital workflows will be standard across the sector by 2026.

The more immediate technology opportunity is in practice operations: AI-driven patient reception, automated clinical documentation, digital intake and consent workflows, and AI-generated referral letters. These are live products with measurable ROI already being deployed at scale. In April 2026, Heidi Health signed a two-year partnership with PortmanDentex to deploy AI clinical scribing across its UK and Irish practices at approximately 60 clinicians per month. PortmanDentex is the UK's second-largest dental group with a professional board and a structured technology governance process. That is exactly why the deal happened cleanly. The governance question is not whether the corporate tier can manage technology adoption. They are demonstrating that they can. The question is whether the mid-market groups below them, the three to 30-site operators who are the next consolidation target, have the board-level oversight to make equivalent decisions with equivalent rigour.

The governance question is not whether to adopt AI in dental operations. That decision is already being made, often at practice or operational level without board oversight. The question is how the board ensures that technology adoption is consistent, compliant, and strategically coherent across the estate rather than fragmented across individual sites. Data residency, UK GDPR compliance, DSP Toolkit alignment, and CQC risk all have board-level dimensions that most dental group boards are not currently equipped to address.

The CMA does not investigate well-governed markets.

The governance gap

The commercial maturation of UK dental has not been matched by a corresponding maturation in governance. The clearest public evidence for this is the CMA study itself. The CMA launched its market study following concerns raised by the Chancellor about hidden costs, lack of transparency, and overtreatment in the private dental market. The study is explicitly examining pricing governance, marketing compliance, corporate ownership structures, and complaint handling, all areas that sit at board level in any well-governed business. The fact that these areas required external regulatory investigation rather than self-correction is itself a governance signal.

The CMA's scope notes that the sector has seen increasing corporatisation and consolidation, and raises questions about whether local competition remains effective where a small number of providers dominate. It is also examining whether ownership models or vertical integration affect patient choice. These are not operational questions. They are governance questions, and they are being asked externally because they have not been asked adequately from within.

Beyond the CMA evidence, the pattern is consistent with what the transaction data shows. A market where 36 per cent of corporate deals involve deferred consideration, where quality practices are selling within weeks with multiple bidders, and where workforce shortages are the single most cited operational concern, is a market moving faster than the governance infrastructure supporting it. The gap is most visible in five areas.

Governance is not a constraint on commercial ambition. It is the condition for it.

What good governance looks like in this market

The dental businesses that will be most resilient through the CMA study, most attractive to PE capital in the next consolidation cycle, and most capable of scaling through technology adoption are not necessarily the largest or the most acquisitive. They are the ones with the governance infrastructure to match their commercial ambition.

At board level

The obvious objection to the governance gap argument is that most dental groups of any scale already employ lawyers, accountants, compliance consultants, and operational advisers. The objection is valid but misses the point. Advisers are episodic and transactional. They are engaged for a specific task and disengage when it is complete. They do not hold the thread between a pricing governance question raised in a CMA information request, a data processing agreement being signed with a new AI vendor, and a deferred consideration structure being negotiated in an acquisition. An independent non-executive director does. The value is not in the individual expertise. It is in the continuous independent oversight that joins those dots across the board's full agenda, and asks the questions that management and their advisers are not always well-positioned to ask of themselves.

Good governance in a dental group requires a board that can hold management to account on clinical quality and commercial performance simultaneously. The regulatory environment now demands that pricing strategy, marketing claims, acquisition rationale, and complaint data are all visible at board level and subject to independent scrutiny. That is a different board function from the one that was adequate five years ago, and it is one that advisers alone cannot fulfil.

On M&A

In a market where 36 per cent of corporate deals involve deferred consideration, where CMA scrutiny of local market concentration is live, and where quality practices are now securing strong offers within weeks of being launched, acquisition governance matters more than it did. Speed of process is increasing the risk of inadequate pre-acquisition diligence. The right questions go beyond price and EBITDA multiple. They are about integration readiness, clinical culture compatibility, regulatory exposure in the acquired portfolio, and the management bandwidth to execute integration without degrading the existing estate.

Boards that treat M&A governance as a transaction function rather than a strategic oversight function will generate integration problems that take years to resolve. The mid-market evidence on this is consistent.

On technology

Technology governance in a dental group does not require a board member with a technology background. It requires a board member who understands enough about how these tools interact with clinical risk, data compliance, and CQC obligations to ensure that management is asking the right questions before adoption rather than managing consequences afterwards.

The specific questions a board should be asking about any new clinical technology include: where is patient data held and under which regulatory framework; what is the DSP Toolkit position; what is the CQC documentation risk; and how is adoption being standardised across the estate rather than allowed to fragment by site.

The fundamentals are strong. The governance infrastructure needs to catch up.

A closing position

Goodwill value stability  |  Fair Maintainable Trade multiple 2017–2026

Year	FMT multiple	Context
2017	3.32	Baseline: pre-consolidation acceleration
2019	3.41	Pre-pandemic peak, rising multiples, cheap capital
2021	3.18	Post-pandemic trough, market disruption
2023	3.09	Market correction, rising rates, corporate pause
2026	3.31	Current: near full recovery, fundamentals intact

UK dental is a genuinely attractive sector. The market fundamentals are strong, the consolidation wave still has distance to run, and the long-term shift in revenue toward private dentistry is structural. The sector is also more dynamic than the simple privatisation narrative captures: NHS practice values are rising again, a new generation of younger clinicians is entering ownership earlier than at any point in the last decade, and the transaction market is more competitive and more sophisticated than it has ever been.

The CMA study is the clearest signal that the sector has reached a scale and commercial significance that attracts serious regulatory scrutiny. That scrutiny will shape the regulatory environment for the next five years regardless of the final report's conclusions. The businesses that navigate this well will be those that have already built the governance infrastructure to respond, not those that begin building it when the recommendations land.

My view is straightforward. The dental sector needs board-level oversight that understands the clinical and commercial dimensions of these businesses simultaneously, can hold the thread across M&A, regulatory, technology, and workforce questions without being episodic, and is independent enough to ask the questions that management and advisers are not always positioned to ask of themselves. That is the governance question the market is not yet asking loudly enough.

---

Andy Sloan  |  Founder, Sloan Strategic Advisory Ltd  |  andy@sloanstrategic.com  |  sloanstrategic.com

This paper represents the personal research and independent opinion of Andy Sloan. It does not represent the views of any organisation with which he is or has been associated.